Beatriz M. Carreno, PhD
Research Associate Professor of Pathology and Laboratory MedicinePerelman School of Medicine at the University of Pennsylvania
Contact InformationPerelman Center for Advanced Medicine
South Tower, 8th Floor
3400 Civic Center Blvd
Philadelphia, PA 19104
Email: bcarreno@upenn.edu
Specialty Division
Immunobiology and Experimental Pathology
Itmat Expertise
My research interests have centered on questions related to the generation and modulation of anti-tumor human T cell immunity and how these responses can be harnessed to develop better immune therapeutics. My laboratory develops methods for (1) identification of tumor antigens, (2) improvement of dendritic cell (DC)-based vaccines and (3) expansion of tumor-specific T cells for clinical applications. Our lab has well-documented experience in the identification and expansion of tumor (shared and neoantigen)-specific CD8+ T cells derived from cancer patients and the development of cellular immunotherapies.
Education
BS Universidad Simon Bolivar, Caracas, Venezuela, 1981
PhD (Microbiology), Georgetown University School of Medicine, 1989
Specialty Certification
Postgraduate Training
Visiting Postdoctoral Fellow, Neuro-immunology, NINDS, NIH, 1989-1991
Postdoctoral Research Associate, Genetics, Washington University School of Medicine, 1991-1995
Awards and Honors
Gran Mariscal de Ayacucho Scholarship, 1978
ITT International Fellowship, 1984-1985
9th International Congress of Immunology Research Award, 1995
Memberships and Professional Organizations
American Association of Immunologists (AAI), 1993 - Present
American Association of Cancer Research (AACR), 2010 - Present
American Association for the Advancement of Science (AAAS), 2015 - Present
Web Links
Selected Publications
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments.
Bhatta, M., Shenoy, G.N., Loyall, J.L., Gray, B.D., Bapardekar, M., Conway, A., Minderman, H., Kelleher, R.J. Jr, Carreno, B.M., Linette, G., Shultz, L.D., Odunsi, K., Balu-Iyer, S.V., Pak, K.Y., Bankert, R.B., J Immunother Cancer 9(10): e003148, 2021, PMID:8488709
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.
Bear, A.S., Blanchard, T., Cesare, J., Ford, M.J., Richman, L.P., Xu, C., Baroja, M.L., McCuaig, S., Costeas, C., Gabunia, K., Scholler, J., Posey, A.D. Jr, O'Hara, M.H., Smole, A., Powell, D.J. Jr, Garcia, B.A., Vonderheide, R.H., Linette, G.P., Carreno, B.M., Nat Commun 12(1): 4365, 2021, PMID:34272369
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
Li, L., Zhang, X., Wang, X., Kim, S.W., Herndon, J.M., Becker-Hapak, M.K., Carreno, B.M., Myers, N.B., Sturmoski, M.A., McLellan, M.D., Miller, C.A., Johanns, T.M., Tan, B.R., Dunn, G.P., Fleming, T.P., Hansen, T.H., Goedegebuure, S.P., Gillanders, W.E., Genome Med 13(1): 56, 2021, PMID:33879241
Preclinical evaluation of cancer immune therapy using patient-derived tumor antigen-specific T cells in a novel xenograft platform.
Shenoy, G.N., Greene, C.J., Bhatta, M., Baroja, M..L, Loyall, J.L., Balu-Iyer, S.V., Kelleher, R.J. Jr, Carreno, B.M., Linette, G.P., Shultz, L.D., Bankert, R.B., Clin Transl Immunology 10(2): e1246, 2021, PMID:33552509
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.
Wells D.K., van Buuren M.M., Dang K.K., Hubbard-Lucey V.M., Sheehan K.C.F., Campbell K.M., Lamb A., Ward J.P., Sidney J., Blazquez A.B., Rech A.J., Zaretsky J.M., Comin-Anduix B., Ng A.H.C., Chour W., Yu T.V., Rizvi H., Chen J.M., Manning P., Steiner G.M., Doan X.C., Merghoub T., Guinney J., Kolom A., Selinsky C., Ribas A., Hellmann M.D., Hacohen N., Sette A., Heath J.R., Bhardwaj N., Ramsdell F., Schreiber R.D., Schumacher T.N., Kvistborg P., Defranoux N.A., Cell 183(3): 818-834, 2020, PMID:33038342
Postvaccination graft dysfunction/aplastic anemia relapse with massive clonal expansion of autologous CD8+ lymphocytes.
Ritz, C., Meng, W., Stanley, N.L., Baroja, M.L., Xu, C., Yan, P., Huang, A.C., Hausler, R., Nicholas, P., Fan, J.M., Lieberman, D., Carreno, B.M., Luning, Prak, E.T., Olson, T.S., Babushok, D.V., Blood Adv 4(7): 1378-1382, 2020, PMID:33038342
CRISPR-engineered T cells in patients with refractory cancer.
Stadtmauer, E.A., Fraietta, J.A., Davis, M.M., Cohen, A.D., Weber, K.L., Lancaster, E., Mangan, P.A., Kulikovskaya, I., Gupta, M., Chen, F., Tian, L., Gonzalez, V.E., Xu, J., Jung, I.Y., Melenhorst, J.J., Plesa, G., Shea, J., Matlawski, T., Cervini, A., Gaymon, A.L., Desjardins, S., Lamontagne, A., Salas-Mckee, J., Fesnak, A., Siegel, D.L., Levine, B.L., Jadlowsky, J.K., Young, R.M., Chew, A., Hwang, W.T., Hexner, E.O., Carreno, B.M., Nobles, C.L., Bushman, F.D., Parker, K.R., Qi, Y., Satpathy, A.T., Chang, H.Y., Zhao, Y., Lacey, S.F., June, C.H., Science 367(6481): eaba7365, 2020, PMID:32029687
Immunological Ignorance is an enabling feature of the oligo-clonal T cell response to melanoma antigens.
Linette, G.P., Becker-Hapak, M., Skidmore, Z.L., Baroja, M.B., Xu, C., Hundal, J., Spencer, D.H., Fu, W., Cummins, C., Robnett, M., Kaabinejadian, S., Hildebrand, W.H., Magrini, V., Demeter, R., Krupnick, A.S., Griffith, O.L., Griffith, M., Mardis, E.R., Carreno, B.M., PNAS 116(47): 23662-23670, 2019
Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era
Linette, G.P., Carreno, B.M., Curr Hematol Malig Rep 14(4): 286, 2019
Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.
Ghasemi, R., Lazear, E., Wang, X., Arefanian, S., Zheleznyak, A., Carreno, B.M., Higashikubo, R., Gelman, A.E., Kreisel, D., Fremont, D.H., Krupnick, A.S., Nat Commun 7(): 12878, 2016, PMID:27650575
